At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 101 enrolled
Drug / intervention
HTD1801 +1 moredrug
Likely dose
HTD1801 250mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adults With NASH and T2DM
In Brief
A Phase 2 clinical trial evaluating HTD1801 and Placebo for Fatty Liver, Nonalcoholic and 5 related conditions. Completed, enrolled 101 participants across 17 sites.
Detailed Summary
Randomized, double-blind, placebo-controlled, parallel-group study comparing multiple doses of HTD1801 to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Digestive System Diseases, Type 2 Diabetes Mellitus (T2DM)
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartNov 2018
Primary CompletionFeb 2020
Study CompletionMar 2020
TodayJul 2026
First PostedSep 4, 2018
Enrollment StartNov 26, 2018
Primary CompletionFeb 7, 2020
Study CompletionMar 9, 2020
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 7.8 years ago
Interventions
HTD1801drug
HTD1801 tablets, 250mg
Placebodrug
tablets manufactured to mimic HTD1801 tablets